< Back to Newsroom

MultiCell Technologies CEO to Present Key Research Data at New York Academy of Sciences' Animal Models Conference CEO Dr. Stephen Chang to Spotlight Company's Proprietary Immune System Modulation Technologies for Treatment of Diabetes and Multiple Sclerosis SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that Chief Executive Officer Dr. Stephen Chang will be one of the featured presenters this week at the New York Academy of Sciences (NYAS) conference to explore new treatments for type-1 diabetes and multiple sclerosis (MS). MultiCell is a leader in the development of novel methods to modulate the immune system to provide potential new treatments for a number of major health threats and unmet medical needs. In particular, MultiCell is focused on the development of MCT-125 and MCT-275. MCT-125 is a first-in-class drug for treatment of chronic fatigue in patients with multiple sclerosis. Currently there are no FDA approved drugs for the treatment of fatigue in patients with MS. MCT-275, also a first-in-class patent protected therapeutic, is indicated for the treatment of early on-set type-1 diabetes. In preclinical animal modes, MCT-275 lowered blood sugar levels to within normal range, and prevented death in the experimental group compared to the control group where all animals died as a result of the excessive blood sugar levels. The New York Academy of Sciences conference, entitled, "How do We Best Employ Animal Models for Type 1 Diabetes and Multiple Sclerosis," is scheduled for November 8-9, 2006. "Our innovative immune modulation technologies are enabling us to advance MCT-175 and MCT-275 as much-needed medical treatments," said Dr. Chang. "We are very excited about sharing our data with our colleagues and building on the momentum we have built over the past year, as we continue to drive the next generation of autoimmune-based therapies to the bedside." Dr. Chang's presentation, entitled, "A Translational Perspective on New Technology," is scheduled for 11:00 am, Nov. 8. The meeting will take place at the Stanford Court hotel in San Francisco, CA. Among the topics of discussion, Dr. Chang will highlight MultiCell's therapeutic pipeline with drug candidates already in various advanced stages of human clinical trials. MCT-125 targets the chronic fatigue symptom in MS patients, while MCT-175 is being developed as a treatment of relapsing-remitting MS. MCT-275 for the treatment of early onset type-1 diabetes. The conference proceedings will be published as a volume of the Annals of the New York Academy of Sciences, a series with a substantial international circulation. The Annals are disseminated globally to scientific, medical, and educational institutions and libraries, and are also available to Academy members and other interested professionals and students. The Institute for Scientific Information rates the Annals in the top 2 percent of more than 4,000 scientific publications. Established in 1817, NYAS has more than 23,000 members in more than 150 countries, with an ever-expanding international membership. Part of the reason for this success is the collection of eBriefings - digital versions of meetings like the one Dr. Chang will be presenting. These eBriefings are not only a major NYAS asset but are also a cutting-edge tool for advancing scientific communication worldwide. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html. Forward Looking Statements Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will", "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could" and "would." Examples of such forward-looking statements include statements regarding developing products that address unmet medical needs. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. MultiCell Technologies, Inc. Dr. Stephen Chang, 858.200.0598 MCETInvestor@MultiCelltech.com or SmallcapInsights.com Dr. John Faessel, 858-587-8590 editors@smallcapinsights.com or Trilogy Capital Partners (Financial Communications) Paul Karon, 800-592-6067 paul@trilogy-capital.com Source: Business Wire (Tuesday November 7, 4:01 pm ET )